Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Elan Ezickson | M | 60 |
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Jeno Gyuris | M | 64 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Ronald DePinho | M | 69 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | 5 ans |
| Karthik Radhakrishnan | M | 53 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Alex M. Cranberg | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Rachel Humphrey | M | 62 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Joseph Kekst | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Amit Rakhit | M | 54 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | 1 ans |
| Richard Jones | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 9 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Robert Z. Orlowski
- Réseau Personnel
